Product Inquiry
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Tesnatilimab | IPH-2301; IPH-23XX; JNJ-4500; JNJ-64304500; NNC-0142-002; NNC-0142-0002; NNC-0142-0000-0002; NN-8555 | Phase 2 Clinical | Innate Pharma | Alopecia Areata; Arthritis, Rheumatoid; Celiac Disease; Inflammation; Crohn Disease | Details |
| NKG2D-ACE2 CAR-NK cell therapy (Sidemu Biotechnology Technology) | Phase 2 Clinical | Coronavirus Disease 2019 (COVID-19) | Details | ||
| QEQ-278 | QEQ-278 | Phase 1 Clinical | Novartis Pharmaceuticals Corp | Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| NKG2D CAR-T Cell therapy (Yake Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Colorectal Neoplasms; Leukemia, Myeloid, Acute | Details | |
| NKG2D CAR-T cell therapy (Uwell Biopharma) | UWN2D | Clinical | Uwell Biopharma | Neoplasms | Details |